Generex Biotechnology Corp Stock News

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Peptide Cancer Vaccine Market finds that Peptide Cancer Vaccine aids to provide tumour-specific T-cells to control or eradicate cancer. This vaccine contains tumour antigens in the form of short or long amino acid sequences. The usage of Peptide Cancer Vaccine to control tumour growth in mouse models is expected to propel the growth of Peptide Cancer Vaccine Market in upcoming years. The total Global Peptide Cancer Vaccine Market is estimated to reach USD 10.07 Billion by 2028. The revenue of the market was USD 4.72 Billion in the year 2021, and is expected to reach with a Compound Annual Growth Rate (CAGR) of 11.2%, states Vantage Market Research, in a report, titled "Peptide Cancer Vaccine Market by Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), by Type (Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex�

MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding c

MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding c

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children's (LCFC) Mission is to help save children's lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our effo

MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to

MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has co

The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conferen

MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 20

MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned p

MIRAMAR, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology

MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company h

MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company h

MIRAMAR, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has sign

MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation ( www.gen erex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock